Researchers from Fudan University and their collaborators reported the synthesis and preclinical characterization of novel Bruton’s tyrosine kinase (BTK)-targeting proteolysis-targeting chimeras (PROTACs) based on ARQ-531, a potent, reversible, noncovalent BTK inhibitor.